Lercanidipino Recordati (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells. This inhibition prevents calcium‑dependent contraction, causing the vessels to dilate. The resulting decrease in peripheral vascular resistance leads to a reduction in systolic and diastolic blood pressure.

The appropriate dose is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. The prescriber will select the starting dose and any subsequent adjustments according to clinical response and tolerability.

Safety data for lercanidipine in pregnancy are limited, and the product is generally not recommended unless the potential benefit justifies the potential risk to the fetus. Likewise, it is not known whether the drug is excreted in human milk; caution is advised for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering a long‑acting vasodilatory effect with once‑daily dosing. Compared with agents such as amlodipine, it has a similar efficacy profile but may differ in pharmacokinetic properties, tolerability, and specific drug‑interaction potential, which clinicians consider when individualising therapy.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture, heat and direct sunlight. Do not use the product after the expiry date printed on the packaging.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, angioedema (swelling of the face, lips, tongue or throat), and significant liver‑enzyme elevations. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the airway, or signs of liver dysfunction such as jaundice.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or those taking strong CYP3A4 inhibitors without appropriate dose adjustment and monitoring.